How does Pancragen compare to diabetes medications?

In a primate study, Pancragen was compared to glimepiride (a sulfonylurea). Both reduced fasting glucose, but Pancragen normalized insulin and C-peptide levels — indicating restored pancreatic function — while glimepiride lowered glucose without improving insulin secretion. Pancragen addresses underlying cellular dysfunction rather than just managing symptoms.

Can Pancragen replace diabetes medication?

No. Pancragen is a research peptide, not an approved treatment. The clinical data, while promising, comes from small studies primarily in Russian research settings. It should never be used as a substitute for prescribed diabetes medication without clinician guidance.

Is Pancragen FDA-approved?

No. Pancragen is not FDA-approved and is not used in mainstream Western medicine. Clinical data comes from Russian research institutions and the Khavinson bioregulator program.

Pancragen

A synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Trp) from the Khavinson system, studied for pancreatic function, glucose metabolism, and age-related type 2 diabetes.

PreliminaryLimited Data

What is Pancragen?

Pancragen is a synthetic tetrapeptide consisting of lysine, glutamic acid, aspartic acid, and tryptophan (Lys-Glu-Asp-Trp, or KEDW), developed by Vladimir Khavinson as part of his bioregulator peptide system. It targets pancreatic tissue — both the insulin-producing beta cells and the enzyme-secreting acinar cells. With 8 PubMed-indexed publications including human clinical data and primate studies, it is one of the better-characterized Khavinson bioregulators. A clinical study in elderly type 2 diabetes patients showed significant reductions in fasting glucose and insulin resistance, and primate studies demonstrated it outperformed glimepiride in normalizing insulin secretion.

Why People Talk About It

Age-related pancreatic dysfunction and type 2 diabetes

Preliminary

Glucose tolerance improvement in elderly

Preliminary

Pancreatic beta-cell function restoration

Emerging

Insulin resistance reduction

Preliminary

Pancreatic cell differentiation in aging

Emerging

How It Works

Pancragen is a four-amino-acid peptide that targets pancreatic cells. It is proposed to enter cell nuclei and activate genes responsible for insulin production and pancreatic cell maintenance. In aging, these genes can become less active — Pancragen may help restore their function, improving the pancreas's ability to regulate blood sugar.

Common Questions

Safety Information

Important Safety Notes

Common Side Effects

Generally well-tolerated in available studiesNo adverse effects reported in primate or human studiesMild injection site reactions possible (injectable form)

Cautions

• Not FDA-approved
• Clinical data from small sample sizes
• May affect blood glucose — requires monitoring in diabetic patients
• Should be used under clinician guidance

What We Don't Know

Western clinical trial data is absent. Human data comes from a single study of 33 type 2 diabetes patients. Long-term effects and interactions with diabetes medications have not been systematically evaluated.

Published Research

8 studies

Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys.

PreclinicalPMID: 28509500

Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys.

PreclinicalPMID: 25946840

Tetrapeptide stimulates functional activity of the pancreatic cells in aging.

PreclinicalPMID: 23734516

Effects of pancragen on the differentiation of pancreatic cells during their ageing.

PreclinicalPMID: 23486591

Peptides tissue-specifically stimulate cell differentiation during their aging.

PreclinicalPMID: 22808515

Prospects of using pancragen for correction of metabolic disorders in elderly people.

Clinical TrialPMID: 22448364

Study of biological activity of Lys-Glu-Asp-Trp-NH2 endogenous tetrapeptide.

PreclinicalPMID: 21246099

Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus.

PreclinicalPMID: 18642713

Mechanism of Action

Pancragen (Lys-Glu-Asp-Trp) is proposed to bind directly to DNA along the major groove, forming stable peptide-DNA complexes that regulate transcription of pancreatic genes. It increases expression of key pancreatic transcription factors including PDX1, NGN3, PAX6, FOXA2, NKX2-2, NKX6.1, and PAX4 — fundamental regulators of beta-cell development and function. In aging pancreatic cultures, it enhances expression of MMP2, MMP9, serotonin, and CD79alpha while reducing apoptosis markers, indicating both functional stimulation and cell survival effects. It also stimulates differentiation factors in acinar and islet cells, with effects more pronounced in aged tissue. In diabetic rat models, oral administration produced hypoglycemic effects while injection normalized endothelial adhesion in mesenteric capillaries, suggesting both metabolic and vascular protective mechanisms.

Evidence Snapshot

Overall Confidence35%

Human Clinical Evidence

Limited but promising. A study of 33 elderly patients with type 2 diabetes showed Pancragen significantly decreased fasting glucose, improved glucose tolerance, and reduced insulin resistance, while also noting that nocturnal melatonin production was reduced 70% in diabetic patients (PMID: 22448364). No Western clinical trials are indexed.

Animal / Preclinical

Moderate. In old rhesus monkeys, Pancragen improved glucose clearance and normalized insulin/C-peptide responses, with benefits persisting 3 weeks post-treatment (PMID: 25946840). It outperformed glimepiride in normalizing insulin secretion in aged primates (PMID: 28509500). Oral Pancragen produced pronounced hypoglycemic effects in diabetic rats and normalized endothelial adhesion (PMID: 18642713). In vitro, it enhanced pancreatic cell differentiation markers in aged cultures (PMID: 23486591, 23734516).

Mechanistic Rationale

Moderate. Multiple studies demonstrate specific effects on pancreatic gene expression: upregulation of key beta-cell transcription factors (PDX1, NGN3, PAX6), stimulation of differentiation markers (MMP2, MMP9, serotonin), and anti-apoptotic effects. The proposed DNA-binding mechanism is consistent with the broader Khavinson framework.

Forms & Administration

Pancragen is available in capsule, sublingual, and injectable formats. In primate studies, intramuscular injection of 50 mcg/day for 10 days was used. Capsule protocols typically involve 1-2 capsules daily for 10-30 days. All peptides should only be used under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Use Cases & Evidence Levels

Age-related pancreatic dysfunction and type 2 diabetes

Preliminary30%

Glucose tolerance improvement in elderly

Preliminary30%

Pancreatic beta-cell function restoration

Emerging50%

Insulin resistance reduction

Preliminary30%

Pancreatic cell differentiation in aging

Emerging50%

Safety Profile

Safety Information

Common Side Effects

Generally well-tolerated in available studiesNo adverse effects reported in primate or human studiesMild injection site reactions possible (injectable form)

Cautions

• Not FDA-approved
• Clinical data from small sample sizes
• May affect blood glucose — requires monitoring in diabetic patients
• Should be used under clinician guidance

What We Don't Know

Published Research

8 studies

Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys.

PreclinicalPMID: 28509500

Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys.

PreclinicalPMID: 25946840

Tetrapeptide stimulates functional activity of the pancreatic cells in aging.

PreclinicalPMID: 23734516

Effects of pancragen on the differentiation of pancreatic cells during their ageing.

PreclinicalPMID: 23486591

Peptides tissue-specifically stimulate cell differentiation during their aging.

PreclinicalPMID: 22808515

Prospects of using pancragen for correction of metabolic disorders in elderly people.

Clinical TrialPMID: 22448364

Study of biological activity of Lys-Glu-Asp-Trp-NH2 endogenous tetrapeptide.

PreclinicalPMID: 21246099

Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus.

PreclinicalPMID: 18642713

All references link directly to PubMed. Citations are selected by clinicians for relevance and quality.

Related Peptides

Epithalon

Preliminary

A synthetic tetrapeptide studied for its potential to activate telomerase and influence cellular aging.

Thymalin

Moderate

A thymic peptide complex studied for immune system restoration, particularly in aging populations and immunocompromised states.

Vesugen

Preliminary

A synthetic tripeptide bioregulator (Lys-Glu-Asp) from the Khavinson system, studied for vascular protection, endothelial function, and age-related cardiovascular decline.

Ovagen

Limited

A synthetic tripeptide bioregulator (Glu-Asp-Leu) from the Khavinson system, studied for liver tissue support, hepatoprotection, and gastrointestinal health.

Pinealon

PreliminaryBeginner

A short tripeptide studied for neuroprotective and cognitive-enhancing properties, part of the Khavinson peptide bioregulator family.

Quick Facts

Class: Bioregulator Peptide
Evidence: Preliminary
Safety: Limited Data
Updated: Apr 2026
Citations: 8PubMed

Also known as

Lys-Glu-Asp-TrpKEDW TetrapeptidePancreas Bioregulator

Evidence Score

Overall Confidence35%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.